| Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE (NCT03673943) | Radiomedix, Inc. | 2018-08-23 |
| Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases (NCT03590119) | Marnix Lam | 2018-08-01 |
| Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel (NCT03562091) | Ipsen | 2018-07-20 |
| Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors (NCT03576040) | University Hospital, Brest | 2018-07-19 |
| DOTATOC PET/CT for Imaging NET Patients (NCT03583528) | British Columbia Cancer Agency | 2018-07-11 |
| Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) (NCT04790708) | University Hospital of Ferrara | 2018-07-02 |
| DEBOXA for Inoperable NET Liver Metastases (NCT03881306) | Xiangya Hospital of Central South University | 2018-07-01 |
| Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors (NCT03420521) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-03-09 |
| Volumetric Imaging Follow up of Patients With Liver Metastases of Small Intestinal Neuroendocrine Tumors (NETs). (NCT03689231) | Hospices Civils de Lyon | 2018-03-01 |
| Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients (NCT03422029) | Peking University | 2018-01-31 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (NCT03290079) | H. Lee Moffitt Cancer Center and Research Institute | 2017-12-15 |
| Entinostat Neuroendocrine (NE) Tumor (NCT03211988) | Antonio Fojo | 2017-12-13 |
| Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (NCT03190213) | University of Utah | 2017-12-04 |
| PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 (NCT03271281) | Rigshospitalet, Denmark | 2017-12-04 |
| Avelumab in G2-3 NET (NCT03278379) | Sunnybrook Health Sciences Centre | 2017-11-15 |
| Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors (NCT03335670) | Yusuf Menda | 2017-11-03 |
| PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 (NCT03278275) | Rigshospitalet, Denmark | 2017-11-01 |
| Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma (NCT03206060) | National Cancer Institute (NCI) | 2017-10-10 |
| A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (NCT05255133) | Universiteit Antwerpen | 2017-10-09 |
| Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms (NCT03288597) | Peking University | 2017-09-01 |
| Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (NCT02943733) | University of Wisconsin, Madison | 2017-08-22 |
| Psychosocial Screening for Neuroendocrine Tumor Patients (NCT03372356) | Peking University | 2017-08-09 |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (NCT02859064) | SCRI Development Innovations, LLC | 2017-07-28 |
| Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain (NCT03220087) | Ipsen | 2017-07-21 |
| Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET (NCT03083210) | Samsung Medical Center | 2017-07-05 |
| 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety (NCT03042416) | University of Alberta | 2017-06-29 |
| Octreotide LAR in the Induction of Immunologic Response in NENs Patients (NCT04129255) | National Cancer Institute, Naples | 2017-06-28 |
| TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors (NCT03079440) | Asan Medical Center | 2017-05-15 |
| 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors (NCT03308682) | Peking Union Medical College Hospital | 2017-04-30 |
| Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors (NCT03478358) | Peking Union Medical College Hospital | 2017-04-30 |
| Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (NCT03095274) | Grupo Espanol de Tumores Neuroendocrinos | 2017-04-11 |
| Study of JS001 in Patients With Advanced Neuroendocrine Tumors (NCT03167853) | Peking University | 2017-04-06 |
| Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors (NCT03112694) | Ipsen | 2017-04-04 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |
| Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression (NCT03014297) | Lowell Anthony, MD | 2017-03-06 |
| Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs (NCT02592707) | Ipsen | 2017-03-06 |
| A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors (NCT03070301) | Memorial Sloan Kettering Cancer Center | 2017-02-27 |
| Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe (NCT04296149) | European Institute of Oncology | 2017-02-16 |
| Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients (NCT03288402) | University Hospitals Coventry and Warwickshire NHS Trust | 2017-02-01 |
| Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma (NCT03022188) | Société Française d'Endoscopie Digestive | 2017-01-10 |
| PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers (NCT02936323) | Tarveda Therapeutics | 2016-12-08 |
| Circulating Tumor Cells and Tumor DNA in HCC and NET (NCT02973204) | University of Aarhus | 2016-11-01 |
| A Study of Pembrolizumab in Patients With Neuroendocrine Tumors (NCT02939651) | Fox Chase Cancer Center | 2016-10-26 |
| The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors (NCT02815969) | University Medical Center Groningen | 2016-09-01 |
| Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors (NCT02743741) | University Health Network, Toronto | 2016-07-15 |
| Identification of Biomarker Profiles GEP-NEN Patients (NCT02838862) | University Hospital Schleswig-Holstein | 2016-07-01 |
| Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors (NCT02691078) | Latin American Cooperative Oncology Group | 2016-07-01 |
| Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors (NCT02810600) | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 2016-06-08 |
| Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors (NCT03454763) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2016-05-26 |
| Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan (NCT03136328) | Montefiore Medical Center | 2016-05-16 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (NCT02611024) | PharmaMar | 2016-05-06 |
| Personalized PRRT of Neuroendocrine Tumors (NCT02754297) | CHU de Quebec-Universite Laval | 2016-04-12 |
| The MetNET-2 Trial (NCT02823691) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2016-04-01 |
| Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy (NCT02749331) | Uppsala University | 2016-03-01 |
| Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation (NCT04140409) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2016-02-02 |
| Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis (NCT02646644) | University Medical Center Groningen | 2016-01-01 |
| Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors (NCT02588170) | Hutchison Medipharma Limited | 2015-12-07 |
| Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors (NCT02589821) | Hutchison Medipharma Limited | 2015-12-07 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267) | Hoffmann-La Roche | 2015-11-19 |
| Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors (NCT02609737) | Memorial Sloan Kettering Cancer Center | 2015-11-13 |
| Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors (NCT02678780) | Grupo Espanol de Tumores Neuroendocrinos | 2015-10-01 |
| Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors (NCT02736500) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2015-09-02 |
| Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors (NCT02441062) | Sue O'Dorisio | 2015-09-01 |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) (NCT02489903) | EpicentRx, Inc. | 2015-06-01 |
| An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours (NCT04440956) | Clarity Pharmaceuticals Ltd | 2015-05-21 |
| Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors (NCT02838342) | Centre Hospitalier Universitaire de Besancon | 2015-05-19 |
| A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours (NCT02402062) | Grupo Espanol de Tumores Neuroendocrinos | 2015-05-11 |
| Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors (NCT02455596) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2015-05-01 |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery (NCT02315625) | National Cancer Institute (NCI) | 2015-04-08 |
| Gallium-68 DOTATOC for Management of Neuroendocrine Tumors (NCT02375464) | Northwell Health | 2015-04-01 |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 (NCT02355535) | Vanquish Oncology, Inc. | 2015-02-01 |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (NCT02299089) | Camurus AB | 2015-01-01 |
| 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies (NCT02348749) | Memorial Sloan Kettering Cancer Center | 2015-01-01 |
| 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) (NCT02359500) | Lale Kostakoglu | 2014-12-01 |
| A Real-world Comparison of FNB and FNA in IHC-required Lesions. (NCT05565066) | Huazhong University of Science and Technology | 2014-12-01 |
| Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study (NCT02279602) | Mateon Therapeutics | 2014-12-01 |
| Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors (NCT02267967) | Hutchison Medipharma Limited | 2014-10-31 |
| Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor (NCT02246127) | Grupo Espanol de Tumores Neuroendocrinos | 2014-10-27 |
| Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer (NCT02174549) | Teclison Ltd. | 2014-09-01 |
| PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation (NCT02134639) | University Hospital, Bordeaux | 2014-09-01 |
| A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers (NCT02132468) | Mateon Therapeutics | 2014-09-01 |
| Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours. (NCT06456723) | Imperial College London | 2014-05-14 |
| 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor (NCT04041882) | Peking Union Medical College Hospital | 2014-04-01 |
| Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan (NCT02102893) | National Health Research Institutes, Taiwan | 2014-02-13 |
| Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study (NCT02067988) | UMC Utrecht | 2014-02-01 |
| Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors (NCT02489604) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2013-12-01 |
| Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate (NCT02125474) | Instituto Nacional de Cancerologia, Columbia | 2013-11-01 |
| Integrated Cancer Repository for Cancer Research (NCT02012699) | University of Nebraska | 2013-11-01 |
| Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors (NCT01967537) | National Cancer Institute (NCI) | 2013-10-18 |
| Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors (NCT02586844) | University Health Network, Toronto | 2013-10-01 |
| Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective (NCT01873248) | Jonsson Comprehensive Cancer Center | 2013-08-26 |
| Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors (NCT01755182) | National Cancer Institute, Naples | 2013-07-01 |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (NCT01794793) | RECORDATI GROUP | 2013-06-10 |
| Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors (NCT06143605) | Yanhong Deng | 2013-01-30 |
| Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (NCT01678664) | Federation Francophone de Cancerologie Digestive | 2012-12-01 |
| Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue (NCT03629847) | King Faisal Specialist Hospital & Research Center | 2012-12-01 |
| Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors (NCT01719861) | Joel Neal | 2012-10-01 |
| Proton Boost for Locally Advanced HEAD AND NECK TUMORS (NCT03183271) | CNAO National Center of Oncological Hadrontherapy | 2012-07-16 |
| Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (NCT01590199) | Novartis Pharmaceuticals | 2012-05-18 |